JOGO-Gx
Commercial- Indications
- Chronic pain, Stroke recovery, Migraine, Neuromuscular disorders
Company intelligence / Profile preview
JOGO Health’s digital therapeutics platform is FDA-cleared and reimbursed by Medicare/commercial insurance. It has treated over 25,000 patients in more than 100,000 sessions across 50+ hospital partners. Clinical data show significant improvements in stroke recovery, reduction of tremors in Parkinson's disease (~70% reduction), and high rates of improvement in pelvic floor dysfunctions. The company received Breakthrough Device Designation from the FDA for its non-invasive therapy targeting chronic lower back pain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JOGO Health.